Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTO NASDAQ:FNCH NYSE:NKGN NYSE:SQZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.71$4.41$1.35▼$50.10$3.66M1.04227,964 shsN/AFNCHFinch Therapeutics Group$7.33-2.3%$9.38$2.00▼$16.10$11.77M1.185,025 shs7,876 shsNKGNNKGen Biotech$0.06$0.09$0.00▼$0.46$7.84M0.664,120 shs2,305 shsSQZSQZ Biotechnologies$0.02$0.02$0.25▼$3.56$708K2.34455,220 shs400 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%0.00%FNCHFinch Therapeutics Group-10.61%-10.06%-8.38%-44.68%-44.34%NKGNNKGen Biotech0.00%0.00%0.00%0.00%-80.00%SQZSQZ Biotechnologies0.00%0.00%0.00%0.00%-14.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.71$4.41$1.35▼$50.10$3.66M1.04227,964 shsN/AFNCHFinch Therapeutics Group$7.33-2.3%$9.38$2.00▼$16.10$11.77M1.185,025 shs7,876 shsNKGNNKGen Biotech$0.06$0.09$0.00▼$0.46$7.84M0.664,120 shs2,305 shsSQZSQZ Biotechnologies$0.02$0.02$0.25▼$3.56$708K2.34455,220 shs400 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%0.00%FNCHFinch Therapeutics Group-10.61%-10.06%-8.38%-44.68%-44.34%NKGNNKGen Biotech0.00%0.00%0.00%0.00%-80.00%SQZSQZ Biotechnologies0.00%0.00%0.00%0.00%-14.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences 0.00N/AN/AN/AFNCHFinch Therapeutics Group 0.00N/AN/AN/ANKGNNKGen Biotech 0.00N/AN/AN/ASQZSQZ Biotechnologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/ANKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/ASQZSQZ Biotechnologies$18.16M0.04N/AN/A$1.94 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/AFNCHFinch Therapeutics Group-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/ANKGNNKGen Biotech-$82.94M-$1.51N/AN/AN/AN/AN/A-479.36%N/ASQZSQZ Biotechnologies-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/ASQZSQZ BiotechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A1.051.05FNCHFinch Therapeutics GroupN/A3.873.87NKGNNKGen BiotechN/A0.020.02SQZSQZ BiotechnologiesN/A3.503.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%FNCHFinch Therapeutics Group21.77%NKGNNKGen Biotech76.17%SQZSQZ Biotechnologies38.51%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences1.33%FNCHFinch Therapeutics Group44.90%NKGNNKGen Biotech10.36%SQZSQZ Biotechnologies16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataFNCHFinch Therapeutics Group1901.61 million885,000No DataNKGNNKGen BiotechN/A130.60 million40.29 millionNot OptionableSQZSQZ Biotechnologies1,62029.49 million24.77 millionNot OptionableAPTO, FNCH, NKGN, and SQZ HeadlinesRecent News About These CompaniesArsenal Yards attracts another life sciences tenantApril 23, 2026 | bizjournals.comFinancial Comparison: SQZ Biotechnologies (NYSE:SQZ) vs. Cortexyme (NASDAQ:CRTX)March 22, 2026 | defenseworld.netDSerica Energy reveals impact of Triton downtime, eyes volume recovery “soonâ€August 5, 2025 | proactiveinvestors.co.ukSQZB SQZ Biotechnologies Company - Seeking AlphaJuly 9, 2025 | seekingalpha.comSerica Energy shares drop as Triton suspended until mid-MarchFebruary 18, 2025 | proactiveinvestors.co.ukSerica Energy says 2025 outlook is ‘promising'January 21, 2025 | proactiveinvestors.co.ukSerica Energy expects to remedy “clearly disappointing†recent production performanceJanuary 7, 2025 | proactiveinvestors.co.ukSQZ Biotechnologies Co Ordinary SharesDecember 23, 2024 | morningstar.comMPortal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round Led by IA VenturesDecember 19, 2024 | finance.yahoo.comGlobal Short-Acting Insulin Market is Expected to Cross ~USD 9 Billion by 2030 | DelveInsightSeptember 5, 2024 | prnewswire.co.ukPSTEMCELL Launches Novel Cell-Engineering CellPore™ Transfection SystemAugust 1, 2024 | valdostadailytimes.comVWhat is the price tag to keep the biotech engine humming in Massachusetts?July 23, 2024 | msn.comSQZ Biotechnologies Company (SQZB)May 22, 2024 | finance.yahoo.comSqz Bio (SQZB) Earnings Dates & ReportsMay 8, 2024 | investing.comVC funding update: who raised money in March?April 1, 2024 | bizjournals.comSQZ, Portal founder Armon Sharei on starting over in biotechMarch 26, 2024 | biopharmadive.comBPortal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VCMarch 19, 2024 | finance.yahoo.comSQZ, months after 80% layoffs, opts for liquidation and $11.8M asset fire sale to StemcellMarch 1, 2024 | fiercebiotech.comFRx Rundown: Gilead Sciences, Latigo Biotherapeutics, Exscientia and moreFebruary 16, 2024 | mmm-online.comMSQZB SQZ Biotechnologies CompanyDecember 28, 2023 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPTO, FNCH, NKGN, and SQZ Company DescriptionsAptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Finch Therapeutics Group NASDAQ:FNCH$7.33 -0.17 (-2.27%) As of 05/12/2026Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.NKGen Biotech NYSE:NKGN$0.06 0.00 (0.00%) As of 05/12/2026 01:35 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.SQZ Biotechnologies NYSE:SQZ$0.02 0.00 (0.00%) As of 05/8/2026SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
